Drug Trial Radar · NCT03977792
An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis
Last checked: Nov 20, 2026Latest source record: Sep 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
164
Planned (sponsor's estimate)
Start
Sep 2020
Primary completion
Jul 2021
Study completion Jul 2022
Sponsor
- Lead sponsor
- Laboratoire Boreaderme Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Ecogene 21
- First posted
- Jun 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BOR15001L7 is a natural product. The primary objective of this study is to demonstrate its non-inferiority to docosanol 10% based on the healing time of cold sores in patients with recurrent herpes labialis.
Conditions
- Recurrent Herpes Labialis
Interventions
BOR15001L7Drug
BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.
Docosanol Cream 10%Drug
Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The mean change of healing timeTime frame: Day 1 to 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.